• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Am J Clin Pathol . Linking Statistics With Testing Policy to Manage COVID-19 in the Community

tetano

Editor, Senior Moderator
Am J Clin Pathol


. 2020 Jun 10;aqaa099.
doi: 10.1093/ajcp/aqaa099. Online ahead of print.
Linking Statistics With Testing Policy to Manage COVID-19 in the Community


Lee H Hilborne[SUP] 1 2 3 [/SUP], Zachary Wagner[SUP] 1 4 [/SUP], Irineo Cabreros[SUP] 1 [/SUP], Robert H Brook[SUP] 1 5 [/SUP]



Affiliations

Abstract

Objectives: To determine the public health surveillance severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing volume needed, both for acute infection and seroprevalence.
Methods: Required testing volumes were developed using standard statistical methods based on test analytical performance, disease prevalence, desired precision, and population size.
Results: Widespread testing for individual health management cannot address surveillance needs. The number of people who must be sampled for public health surveillance and decision making, although not trivial, is potentially in the thousands for any given population or subpopulation, not millions.
Conclusions: While the contributions of diagnostic testing for SARS-CoV-2 have received considerable attention, concerns abound regarding the availability of sufficient testing capacity to meet demand. Different testing goals require different numbers of tests and different testing strategies; testing strategies for national or local disease surveillance, including monitoring of prevalence, receive less attention. Our clinical laboratory and diagnostic infrastructure are capable of incorporating required volumes for many local, regional, and national public health surveillance studies into their current and projected testing capacity. However, testing for surveillance requires careful design and randomization to provide meaningful insights.

Keywords: COVID-19; Coronavirus; Laboratory; Public health; SARS-CoV-2; Surveillance.
 
Back
Top Bottom